Lifeboat Foundation

Trial also will test pausing immunosuppressive medication to improve antibody response.

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

“Many people who have an autoimmune disease that requires immunosuppressive therapy have had a poor immune response to the authorized and approved COVID-19 vaccines, placing these individuals at high risk for the disease,” said NIAID Director Anthony S. Fauci, M.D. “We are determined to find ways to elicit a protective immune response to the vaccines in this population. This new study is an important step in that direction.”

As the middle child of the “DNA to RNA to protein” central dogma, RNA didn’t get much press until its Covid-19 vaccine contribution. But the molecule is a double hero: it both carries genetic information, and—depending on its structure—can catalyze biological functions, regulate which genes are turned on, tweak your immune system, and even crazier, potentially pass down “memories” through generations.

It’s also frustratingly difficult to understand.

Similar to proteins, RNA also folds into complicated 3D structures. The difference, explain Drs. Rhiju Das and Ron Dror at Stanford University, is that we comparatively know so little about these molecules. There are 30 times as many types of RNA as there are proteins, but the number of deciphered RNA structures is less than one percent compared to proteins.

A good start if you are a sufferer. There are many studies and trials for working toward a cure. Keep searching.

Aug. 20 (UPI) — Antibody therapy may help prevent the development of celiac disease, the digestive disorder that limits the body’s ability to process foods that contain wheat, barley and rye, a study published Friday by Science Immunology found.

The approach uses specially modified monoclonal, or laboratory-created, antibodies that prevent the human immune system from recognizing gluten, a protein found in these foods, as a toxin, the researchers said.

Continue reading “Specially designed monoclonal antibodies may prevent celiac disease, study finds” »

Science from industry, federal agencies and independent researchers now links 6:2 FTOH to kidney disease, cancer, neurological damage, developmental problems, mottled teeth and autoimmune disorders, while researchers also found higher mortality rates among young animals and human mothers exposed to the chemicals.

Experts previously considered food and water to be the two main routes by which humans are exposed to PFAS, but the study’s authors note that many humans spend about 90% of their time indoors, and the findings suggest that breathing in the chemicals probably represents a third significant exposure route.

“It’s an underestimated and potentially important source of exposure to PFAS,” said Tom Bruton, a co-author and senior scientist at Green Science.

Continue reading “Toxic ‘forever chemicals’ contaminate indoor air at worrying levels, study finds” »

This is a truly enlightening 5 min. excerpt by Liz Parrish on gene therapy and its suitability to achieve radical life extension. Among other important aspects, Liz tells us about how regulatory constrains are delaying progress in this important vehicle to treat incurable diseases and aging itself. I added subtitles in Spanish. Don’t miss it!!! In the description of the video is the link to the entire interview.

Este es un extracto muy esclarecedor por parte de Liz Parrish sobre la terapia génica y su idoneidad para lograr una prolongación radical de la vida. Entre otros aspectos importantes, Liz nos cuenta cómo las restricciones regulatorias están retrasando el progreso de este importante vehículo, para tratar enfermedades incurables y el envejecimiento en sí mismo. Le he agregado subtítulos en español. No te lo pierdas!!! En la descripción del video está el enlace a toda la entrevista.

Continue reading “Liz Parrish considerations on gene therapy (excerpts from an interview) (con S/T en Español)” »

Wide Area Networks (WANs), the global backbones and workhorses of today’s internet that connect billions of computers over continents and oceans, are the foundation of modern online services. As COVID-19 has placed a vital reliance on online services, today’s networks are struggling to deliver high bandwidth and availability imposed by emerging workloads related to machine learning, video calls, and health care.

To connect WANs over hundreds of miles, fiber optic cables that transmit data using light are threaded throughout our neighborhoods, made of incredibly thin strands of glass or plastic known as optical fibers. While they’re extremely fast, they’re not always reliable: They can easily break from weather, thunderstorms, accidents, and even animals. These tears can cause severe and expensive damage, resulting in 911 service outages, lost connectivity to the internet, and inability to use smartphone apps.

Continue reading “ARROW, a reconfigurable fiber optics network, aims to take on the end of Moore’s law” »

In 2,001 Celera Genomics and the International Human Genome Sequencing Consortium published their initial drafts of the human genome, which revolutionized the field of genomics. While these drafts and the updates that followed effectively covered the euchromatic fraction of the genome, the heterochromatin and many other complex regions were left unfinished or erroneous. Addressing this remaining 8% of the genome, the Telomere-to-Telomere (T2T) Consortium has finished the first truly complete 3.055 billion base pair (bp) sequence of a human genome, representing the largest improvement to the human reference genome since its initial release. The new T2T-CHM13 reference includes gapless assemblies for all 22 autosomes plus Chromosome X, corrects numerous errors, and introduces nearly 200 million bp of novel sequence containing 2,226 paralogous gene copies, 115 of which are predicted to be protein coding. The newly completed regions include all centromeric satellite arrays and the short arms of all five acrocentric chromosomes, unlocking these complex regions of the genome to variational and functional studies for the first time.

The latest major update to the human reference genome was released by the Genome Reference Consortium (GRC) in2013and most recently patched in2019(GRCh38.p13). This assembly traces its origin to the publicly funded Human Genome Project and has been continually improved over the past two decades. Unlike the competing Celera assembly , and most modern genome projects that are also based on shotgun sequence assembly , the GRC human reference assembly is primarily based on Sanger sequencing data derived from bacterial artificial chromosome (BAC) clones that were ordered and oriented along the genome via radiation hybrid, genetic linkage, and fingerprint maps. This laborious approach resulted in what remains one of the most continuous and accurate reference genomes today. However, reliance on these technologies limited the assembly to only the euchromatic regions of the genome that could be reliably cloned into BACs, mapped, and assembled.

One of the most difficult aspects of gene therapy might be ensuring that it gets into the right cells safely so it can have a therapeutic effect. Researchers have now created a new way to deliver various types of RNA cargo to cells, which utilizes one of the human body’s natural proteins to create particles that can bind to RNA. This approach, called SEND, may help reduce any immune response that would be mounted against a gene therapy. The work has been reported in Science.

Current delivery systems are not efficient, may integrate their cargo improperly, and can cause serious immune reactions. “The biomedical community has been developing powerful molecular therapeutics, but delivering them to cells in a precise and efficient way is challenging,” said senior study author Feng Zhang, Ph.D., a core institute member at the Broad Institute, among many other appointments. “SEND has the potential to overcome these challenges.”

Newly released data confirms that the Pfizer-BioNTech and Moderna vaccines are both associated with rare heart problems, and that this side effect is most common after the second shot in adolescent boys and young men. Still, the benefits of vaccination continued to outweigh the risks, scientists said.

The side effects tend to be mild, temporary and uncommon. For every million doses of the second shot given to 12-to 39-year-olds, there were 14 to 20 extra cases of the heart problems, according to the new data, which was presented Monday at a meeting of an independent advisory committee to the Centers for Disease Control and Prevention.

“The data suggest an association of myocarditis with mRNA vaccination in adolescents and young adults,” Dr. Grace Lee, a pediatrician at Stanford and chair of the committee, said at the meeting. “Further data are being compiled to understand potential risk factors, optimal management strategies and long-term outcomes.”